Indication

Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Medicine details

Medicine name:
osimertinib (Tagrisso)
SMC ID:
SMC2383
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 November 2021
SMC meeting date:
05 October 2021
Patient group submission deadline:
02 August 2021